C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 110 filers reported holding C4 THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,054,511 | -32.4% | 1,642,210 | 0.0% | 0.34% | -26.5% |
| Q2 2023 | $4,516,078 | +87471.8% | 1,642,210 | 0.0% | 0.46% | -27.9% |
| Q1 2023 | $5,157 | -46.8% | 1,642,210 | 0.0% | 0.64% | -40.4% |
| Q4 2022 | $9,689 | -99.9% | 1,642,210 | 0.0% | 1.08% | -37.0% |
| Q3 2022 | $14,402,000 | +16.3% | 1,642,210 | 0.0% | 1.72% | +18.4% |
| Q2 2022 | $12,382,000 | -68.9% | 1,642,210 | 0.0% | 1.45% | -62.5% |
| Q1 2022 | $39,840,000 | -24.7% | 1,642,210 | 0.0% | 3.87% | -7.7% |
| Q4 2021 | $52,879,000 | -27.9% | 1,642,210 | +0.0% | 4.19% | -7.9% |
| Q3 2021 | $73,374,000 | +18.1% | 1,642,209 | 0.0% | 4.55% | +11.8% |
| Q2 2021 | $62,141,000 | +2.3% | 1,642,209 | 0.0% | 4.07% | +18.3% |
| Q1 2021 | $60,745,000 | +11.7% | 1,642,209 | 0.0% | 3.44% | +0.7% |
| Q4 2020 | $54,406,000 | – | 1,642,209 | – | 3.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |